N-(2-amino-3-methyl-valeryl)-leucine | 26462-22-6

• 物质功能分类: 生物 - ELISA 试剂盒
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(2-amino-3-methyl-valeryl)-leucine
• 英文别名: N-(2-Amino-3-methyl-valeryl)-leucin; 'N-Isoleucyl-leucin'；N-(2-Amino-3-methyl-valeryl)-leucin；2-[(2-azaniumyl-3-methylpentanoyl)amino]-4-methylpentanoate
• CAS: 26462-22-6
• 化学式: C₁₂H₂₄N₂O₃
• mdl: MFCD13247795
• 分子量: 244.334
• InChiKey: JWBXCSQZLLIOCI-UHFFFAOYSA-N

物化性质

• 沸点：
  432.7±30.0 °C(Predicted)
• 密度：
  1.051±0.06 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  92.4
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2924199090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为产物：
  描述：

  2-bromo-3-methyl-valeryl chloride 在 sodium hydroxide 、 氨 、 水 作用下， 生成 N-(2-amino-3-methyl-valeryl)-leucine
  参考文献：
  名称：

  Gallagher et al., Journal of the Chemical Society, 1952, p. 4870,4873

  摘要：

  DOI：

文献信息

• SUBSTRATE FOR ASSAYING BETA-GLUCAN AND/OR ENDOTOXIN AND ASSAY METHOD
  申请人：Kitagawa Takeshi

  公开号：US20100330700A1

  公开（公告）日：2010-12-30

  An object of the present invention is to provide a peptide derivative for determining β-glucan or endotoxin which allows high sensitivity measurement, and a method for determining β-glucan and/or endotoxin using the same. The present invention relates to (1) a peptide derivative represented by the following general formula [1]: X-A 1 -Gly-Arg-A 2 -E-D  [1], (2) a reagent for determining β-glucan and/or endotoxin comprising the above-described peptide derivative, (3) a method for determining β-glucan and/or endotoxin, characterized in that a sample containing β-glucan and/or endotoxin, an amebocyte lysate of a horseshoe crab and the above-described peptide derivative are reacted each other, then the resulting released compound represented by the following general formula [2]: H-A 2 -E-D  [2] is separated from unreacted substance and quantified, and the determination is made based on this value, and (4) a reagent kit for determining β-glucan and/or endotoxin, comprising an amebocyte lysate of a horseshoe crab and the above-described peptide derivative as constituents thereof.

  本发明的目的是提供一种用于测定β-葡聚糖或内毒素的肽衍生物，该肽衍生物允许高灵敏度测量，并提供使用该肽衍生物测定β-葡聚糖和/或内毒素的方法。本发明涉及(1)由以下通式[1]表示的肽衍生物：X-A1-Gly-Arg-A2-E-D[1]，(2)用上述肽衍生物的试剂用于测定β-葡聚糖和/或内毒素，(3)一种用于测定β-葡聚糖和/或内毒素的方法，其特征在于将含有β-葡聚糖和/或内毒素的样品、一种马蹄蟹的阿米巴溶解液和上述肽衍生物反应，然后分离出代表以下通式[2]的所释放的化合物：H-A2-E-D[2]，并对此值进行定量测定，然后进行测定，以及(4)用于测定β-葡聚糖和/或内毒素的试剂盒，其包括一种马蹄蟹的阿米巴溶解液和上述肽衍生物作为其组分。
• Dry compositions comprising hydrophobic stabilisers
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP1424066A1

  公开（公告）日：2004-06-02

  The object of the present invention is to provide a dry composition having the following advantageous properties. That is, even when left in a highly humid environment, the dry composition of the present invention scarcely loses its pharmacological activity, does not deliquesce and retains its dry state over a long period of time. A dry composition of the present invention comprises at least one of active ingredients selected from the group consisting of pharmacologically active proteins and pharmacologically active polypeptides and as a stabilizer at least one of hydrophobic stabilizers selected from the group consisting of hydrophobic amino acids, hydrophobic dipeptides and hydrophobic tripeptides.

  本发明的目的是提供一种具有以下优点的干燥组合物。也就是说，即使将本发明的干燥组合物置于高度潮湿的环境中，它也几乎不会失去药理活性，不会潮解，并能长期保持干燥状态。 本发明的干性组合物包括至少一种选自药理活性蛋白质和药理活性多肽组的活性成分，以及至少一种选自疏水氨基酸、疏水二肽和疏水三肽组的疏水稳定剂。
• TRYPTOPHAN AS A BIOMARKERS FOR KIDNEY FUNCTION AND METHODS USING THE SAME
  申请人：Metabolon, Inc.

  公开号：EP3410115A1

  公开（公告）日：2018-12-05

  Biomarkers of kidney function and methods for using said biomarkers for assessing kidney function, monitoring kidney function, diagnosing acute kidney injury, and diagnosing chronic kidney disease are provided. Also provided are suites of small molecule entities as biomarkers for chronic kidney disease.

  本研究提供了肾功能生物标志物以及使用上述生物标志物评估肾功能、监测肾功能、诊断急性肾损伤和诊断慢性肾病的方法。此外，还提供了作为慢性肾病生物标志物的小分子实体套件。
• Blood based biomarkers for diagnosing atherosclerotic coronary artery disease
  申请人：Global Genomics Group, LLC

  公开号：US10254272B2

  公开（公告）日：2019-04-09

  The invention, in some aspects, relates to methods for evaluating a human subject for having atherosclerotic coronary artery disease (ASCAD) or as having a coronary atherosclerotic plaque. In some aspects, the invention relates to methods and kits useful for diagnosing, classifying, profiling and treating atherosclerotic CAD and or a coronary atherosclerotic plaque.

  在某些方面，本发明涉及评估人体是否患有冠状动脉粥样硬化性疾病（ASCAD）或冠状动脉粥样硬化斑块的方法。在某些方面，本发明涉及用于诊断、分类、剖析和治疗动脉粥样硬化性冠状动脉疾病和或冠状动脉粥样硬化斑块的方法和试剂盒。
• Small molecule metabolites for the diagnosis of bacterial vaginosis and assessment of disease risk
  申请人：Fred Hutchinson Cancer Research Center

  公开号：US10690651B2

  公开（公告）日：2020-06-23

  The invention disclosed herein generally relates to methods and kits for diagnosing, assessing disease risk, treating, and preventing bacterial vaginosis (BV) and associated conditions. Additional embodiments include methods for developing metabolic profiles associated with increased disease risk, and developing new approaches to treat BV based on interrupting metabolic networks.

  本文公开的发明一般涉及诊断、评估疾病风险、治疗和预防细菌性阴道病（BV）及相关疾病的方法和试剂盒。其他实施方案包括开发与疾病风险增加相关的代谢图谱的方法，以及开发基于干扰代谢网络治疗 BV 的新方法。